GUTSNasdaq

Fractyl Health Inc.

Healthcare·Metabolic·Phase 3·Burlington, MA, United States
Metabolic

Fractyl Health Inc. (GUTS): 4 pipeline candidates · 1 upcoming catalyst · ~9 mo cash runway · 4 clinical trials. Updated within the last hour.

5.2/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway2.5

9.0 months

Financial Health5.0

D/E 3.65 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst Momentum3.0

1 upcoming, next in ~104d

Insider SignalN/A

N/A

A transparent, data-derived signal for Fractyl Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$123.1M

Cash

$67.4M

Quarterly Burn

$22.5M

Runway

9.0 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2027
Today~10 mo out
Catalyst within runway

Pipeline (4 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

78

Total value held

$19.3M

HolderSharesValue
vanguard capital management llc11,066,012$5.1M
683 capital management, llc6,727,235$3.1M
maverick capital ltd3,974,806$1.8M
blackrock, inc.2,139,837$980K
m28 capital management lp1,856,117$850K
silverarc capital management, llc1,701,625$779K
ubs group ag1,622,163$743K
geode capital management, llc1,435,261$657K
adar1 capital management, llc1,428,571$654K
cm management, llc1,400,000$641K

Showing top 10 of 78 institutional holders of Fractyl Health Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

4 clinical trials·1 FDA decision·CEO: Dr. Harith Rajagopalan M.D., Ph.D.

Frequently asked questions

How many drug candidates are in Fractyl Health Inc.'s pipeline?

Fractyl Health Inc. (GUTS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Fractyl Health Inc.'s lead drug candidate?

Fractyl Health Inc.'s most advanced tracked candidate is revita (Phase 3) for Weight maintenance in people with obesity who discontinue GLP-1 based therapy.

What is Fractyl Health Inc.'s next catalyst?

Fractyl Health Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: revita" — expected September 30, 2026.

What is Fractyl Health Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Fractyl Health Inc. has approximately 9.0 months of cash runway.

What is Fractyl Health Inc.'s market capitalization?

Fractyl Health Inc.'s market capitalization is approximately $123.1M.

Get the full picture on Fractyl Health Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.